Fenofibrate

Because the science underpinning medicine evolves so quickly, it is not uncommon for some doctors to manage patients based on old evidence that is no longer a best practice; this is called clinical inertia.

ORLANDO — The generic lipid-lowering drug fenofibrate was associated with a significant reduction in progression of diabetic retinopathy and maculopathy, researchers reported.

Fenofibrate was associated with a reduction in heart failure hospitalizations and cardiovascular-related mortality compared with placebo in patients with type 2 diabetes who received simvastatin, according to recent data.

In a cohort of patients with type 2 diabetes treated with simvastatin, fenofibrate decreased the composite of heart failure hospitalizations or cardiovascular mortality, according to an analysis of the ACCORD Lipid trial.

Primary biliary cholangitis is a chronic autoimmune disease that causes progressive destruction of the bile ducts. While the disease is considered rare with fewer than 200,000 cases in the U.S. per year, many physicians and patient advocacy groups have made strides toward increasing awareness about the disease, as early diagnosis and treatment can help to manage complications and prevent progression of inflammation and fibrosis.